GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologic solutions, announced today its lineup of products to be unveiled at the company’s educational exhibit, Booth #3881, at the American Academy of Orthopedic Surgeons (AAOS) 2016 Annual Meeting, March 1-5 in Orlando, Fla.
“We have focused our recent development efforts on delivering innovations that resolve some of the most complex and challenging demands that orthopaedic surgeons face in the O.R. -- revision total joint surgery,” said Exactech Chief Executive Officer David Petty. “We are eager to launch three new revision implant and instrumentation systems this year and to share updates to our InterSpace® spacers, AcuDriver® cement removal systems and biologic solutions, which fully equip surgeons to tackle whatever they face when revising a total joint implant.”
Highlights of Exactech’s latest innovations for revision arthroplasty include:
- The only modular device for reverse shoulder arthroplasty with significant proximal bone loss, the Equinoxe® Humeral Reconstruction Prosthesis offers a unique and stable solution for complex and challenging humeral reconstruction cases. *
- Exactech’s new comprehensive Revision Knee System delivers a high-performance portfolio of implants, instruments and advanced surgical technology for reproducible results in a streamlined revision procedure.
- The Alteon® Monobloc Revision Femoral Stem incorporates the functionality of a modular design with the simplicity of a monobloc stem. A press-fit, distally fixed, one-piece tapered, splined titanium stem, it is designed to improve surgical experiences and clinical outcomes.
- The newest addition to the InterSpace® family, the Tapered Wedge Hip Spacer, allows surgeons to more conservatively treat patients following a peri-prosthetic joint infection of a wedge-style hip stem. Exactech is pleased to share the data behind InterSpace’s preformed spacer technology with 20+ years’ clinical experience.
Also an important complement to revision surgery, Exactech offers biologic solutions such as Optecure®, an engineered bone graft for reconstruction of the spine, pelvis and extremities. Optecure and Optecure+CCC can be used in complex cases to help repair bone defects.
In addition to a renewed focus on revision total joint arthroplasty, Exactech’s technical staff and surgeon consultants will share their experiences with other recent market introductions such as the Alteon® Tapered Wedge Femoral Stem and enhancements to the Equinoxe® platform shoulder system. A focal point of Exactech’s educational exhibit will be live demonstrations of ExactechGPS® Guided Personalized Surgery system, a computer-assisted technology which supports the Optetrak Logic® comprehensive primary knee system.
Visit www.exac.com/academy for more information on featured products, scheduled clinical experts and live demonstrations.
*The Equinoxe Humeral Reconstruction Prosthesis is not indicated for use with the reverse shoulder components in oncology applications.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.